Mi­cro­bio­me up­start Vedan­ta gets an ex­tra $18.5M in the bank, wrap­ping up $45.5 Se­ries C round

Apart from a few pit­falls, such as Seres Ther­a­peu­tics’ sem­i­nal ef­fort in­to de­vel­op­ing a “crap­sule” — the emerg­ing field aim­ing to har­ness in­sights gained from gut mi­cro­bio­ta to de­vel­op drugs has at­tract­ed a buck­et of biobucks and even in­spired the takeover of a key play­er, Re­bi­otix. The en­thu­si­asm per­sists, with up­start Vedan­ta Bio­sciences at­tract­ing an ad­di­tion­al $18.5 mil­lion in its Se­ries C round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER